MOACM
ALXN

Mutual of America Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Mutual of America Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-28,878
Closed -$5.3M – 1677
2021
Q2 		$5.3M Buy
28,878
+394
+1% +$67.6K 0.05% 497
2021
Q1 		$4.36M Buy
28,484
+916
+3% +$142K 0.05% 595
2020
Q4 		$4.31M Sell
27,568
-874
-3% -$112K 0.05% 536
2020
Q3 		$3.25M Sell
28,442
-1,363
-5% -$147K 0.04% 582
2020
Q2 		$3.35M Sell
29,805
-355
-1% -$37.7K 0.05% 555
2020
Q1 		$2.71M Buy
30,160
+107
+0.4% +$10.5K 0.05% 555
2019
Q4 		$3.25M Sell
30,053
-6
-0% -$642 0.04% 678
2019
Q3 		$2.94M Buy
30,059
+118
+0.4% +$13.3K 0.04% 691
2019
Q2 		$3.92M Buy
29,941
+369
+1% +$47.6K 0.06% 522
2019
Q1 		$4M Sell
29,572
-176
-0.6% -$21.9K 0.06% 517
2018
Q4 		$2.9M Buy
29,748
+945
+3% +$112K 0.05% 613
2018
Q3 		$4M Buy
28,803
+92
+0.3% +$11.5K 0.06% 524
2018
Q2 		$3.56M Buy
28,711
+299
+1% +$34.9K 0.05% 588
2018
Q1 		$3.17M Buy
28,412
+915
+3% +$109K 0.05% 628
2017
Q4 		$3.29M Buy
27,497
+715
+3% +$87.1K 0.05% 614
2017
Q3 		$3.76M Sell
26,782
-656
-2% -$89.1K 0.06% 517
2017
Q2 		$3.34M Sell
27,438
-557
-2% -$64.8K 0.06% 564
2017
Q1 		$3.39M Buy
27,995
+1,049
+4% +$135K 0.06% 540
2016
Q4 		$3.3M Buy
26,946
+518
+2% +$63.4K 0.06% 526
2016
Q3 		$3.24M Buy
26,428
+248
+0.9% +$31.9K 0.07% 495
2016
Q2 		$3.06M Buy
26,180
+805
+3% +$114K 0.07% 485
2016
Q1 		$3.53M Buy
25,375
+228
+0.9% +$33.5K 0.08% 367
2015
Q4 		$4.8M Buy
25,147
+118
+0.5% +$20.6K 0.11% 225
2015
Q3 		$3.91M Sell
25,029
-8,626
-26% -$1.57M 0.09% 289
2015
Q2 		$6.08M Buy
33,655
+11,283
+50% +$1.95M 0.13% 151
2015
Q1 		$3.88M Buy
22,372
+964
+5% +$174K 0.08% 337
2014
Q4 		$3.96M Buy
21,408
+316
+1% +$58.6K 0.09% 319
2014
Q3 		$3.5M Buy
21,092
+50
+0.2% +$8.21K 0.08% 341
2014
Q2 		$3.29M Sell
21,042
-554
-3% -$87.5K 0.08% 398
2014
Q1 		$3.29M Buy
21,596
+931
+5% +$148K 0.08% 389
2013
Q4 		$2.75M Sell
20,665
-233
-1% -$28K 0.07% 488
2013
Q3 		$2.43M Buy
20,898
+475
+2% +$52.1K 0.07% 487
2013
Q2 		$1.88M Buy
+20,423
New +$1.97M 0.06% 596

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Mutual of America Capital Management's ALXN Position: Q3 2021 in Review

Mutual of America Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 28,878 shares — an estimated $5.3M sold.

Mutual of America Capital Management first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $6.08M in Q2 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Mutual of America Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Mutual of America Capital Management sold 28,878 Alexion Pharmaceuticals shares in Q3 2021, an estimated $5.3M.
  • Mutual of America Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Mutual of America Capital Management's Alexion Pharmaceuticals position peaked at $6.08M in Q2 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Mutual of America Capital Management's 13F filing for Q3 2021, filed 10 Nov 2021.